Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

ALLK


Top 10 Correlated ETFs

ALLK


Top 10 Correlated Stocks

ALLK


In the News

11:48 03 Oct 2022 ALLK

3 Healthcare Stocks to Sell Before They Die

The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.

12:56 03 Oct 2022 ALLK

Why Is Allakos (ALLK) Stock Soaring 25% Today?

On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before paring back modestly heading into the early afternoon hours. Specifically, the company — which focuses on developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases — announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share.

02:10 03 Oct 2022 ALLK

Why Allakos Stock Is on Fire Today

Investors appear to be getting into position ahead of a major upcoming catalyst.

10:39 03 Oct 2022 ALLK

Why Allakos Stock Sank 17.3% in February

The biotech stock has lost roughly 96% of its value over the last year.

04:53 03 Oct 2022 ALLK

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

07:05 03 Oct 2022 ALLK

Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know

Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.

08:00 03 Oct 2022 ALLK

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.

01:53 03 Oct 2022 ALLK

5 Important Investing Lessons From Allakos' Price Collapse

ALLK stock is a gamble now even after falling about 85% off its 52-week high. Allakos' slide offers investors with a learning opportunity.

12:09 03 Oct 2022 ALLK

Allakos Is a Cautionary Tale of Biopharmaceutical Investing

ALLK stock dropped off a cliff following disappointing study results, which illustrates what can go wrong in risky biopharma equities. The post Allakos Is a Cautionary Tale of Biopharmaceutical Investing appeared first on InvestorPlace.

08:17 03 Oct 2022 ALLK

Why Allakos Stock Plummeted 87.5% in the Last Month of 2021

The biotech stock is now down roughly 93% over the last year.

Financial details

Company Rating
Neutral
Market Cap
335.65M
Income
-578.72M
Revenue
0
Book val./share
4.07
Cash/share
3.88
Dividend
-
Dividend %
-
Employees
192
Optionable
No
Shortable
Yes
Earnings
07 Nov 2022
P/E
-0.58
Forward P/E
-
PEG
-0.04
P/S
-
P/B
1.51
P/C
1.58
P/FCF
-0.96
Quick Ratio
5.82
Current Ratio
6.08
Debt / Equity
0.21
LT Debt / Equity
0.21
-
-
EPS (TTM)
-7.39
EPS next Y
-
EPS next Q
-
EPS this Y
61.61%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-75%
-
-
-
-
SMA20
29.74%
SMA50
47.73%
SMA100
53.46%
Inst Own
64.14%
Inst Trans
-4.91%
ROA
-189%
ROE
-159%
ROC
-1.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
54.84M
Shs Float
39.46M
-
-
-
-
Target Price
218
52W Range
2.54-112.87
52W High
-94.54%
52W Low
+206%
RSI
63.69
Rel Volume
1.52
Avg Volume
2.1M
Volume
3.19M
Perf Week
10.47%
Perf Month
72.88%
Perf Quarter
7.37%
Perf Half Y
4.62%
-
-
-
-
Beta
0.647785
-
-
Volatility
0.31%, 0.64%
Prev Close
9.29%
Price
6.12
Change
9.09%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000
Net income per share
-2.2-1.89-3.1-5.45
Operating cash flow per share
-1.94-1.39-2.3-4.2
Free cash flow per share
-2.29-1.41-2.31-4.87
Cash per share
9.0210.9713.328.57
Book value per share
9.2810.9713.229
Tangible book value per share
9.2810.9713.229
Share holders equity per share
9.2810.9713.229
Interest debt per share
0.010.010.011.98
Market cap
773.69M3.48B6.6B316.25M
Enterprise value
740.15M3.44B6.39B261.63M
P/E ratio
-17.77-40.78-42.99-1.17
Price to sales ratio
0000
POCF ratio
-20.12-55.25-57.92-1.52
PFCF ratio
-17.04-54.58-57.6-1.31
P/B Ratio
4.27.0210.080.71
PTB ratio
4.27.0210.080.71
EV to sales
0000
Enterprise value over EBITDA
-16.27-38.3-41.1-0.98
EV to operating cash flow
-19.25-54.65-56.11-1.26
EV to free cash flow
-16.3-53.99-55.8-1.09
Earnings yield
-0.06-0.02-0.02-0.85
Free cash flow yield
-0.06-0.02-0.02-0.76
Debt to equity
0000.11
Debt to assets
0.040.040.090.17
Net debt to EBITDA
0.740.421.330.2
Current ratio
34.5538.2729.8111.22
Interest coverage
0000
Income quality
0.880.740.740.77
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0.180.010.010.16
Capex to revenue
0000
Capex to depreciation
-28.7-0.51-0.41-9.8
Stock based compensation to revenue
0000
Graham number
21.4121.5930.3733.23
ROIC
-0.25-0.18-0.23-0.55
Return on tangible assets
-0.23-0.17-0.21-0.5
Graham Net
8.6510.5126.77
Working capital
176.35M486.81M646.82M411.33M
Tangible asset value
0000
Net current asset value
174.34M478.7M604.04M362.23M
Invested capital
0000.22
Average receivables
0000
Average payables
8.03M9.96M13.96M13.83M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.24-0.17-0.23-0.61
Capex per share
-0.35-0.02-0.01-0.67

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-1.07-1.16-4.96-3.6-0.9
Operating cash flow per share
-0.93-0.86-1.2-3.19-0.6
Free cash flow per share
-1.05-1.05-1.49-3.23-0.65
Cash per share
10.439.357.84.513.88
Book value per share
10.649.78.194.754.07
Tangible book value per share
10.649.78.194.754.07
Share holders equity per share
10.649.78.194.754.07
Interest debt per share
0.941.041.810.940.95
Market cap
4.58B5.72B532.49M311.71M171.52M
Enterprise value
4.43B5.51B477.86M326.69M140.81M
P/E ratio
-20.02-22.81-0.49-0.4-0.87
Price to sales ratio
00000
POCF ratio
-92.04-123.28-8.14-1.79-5.23
PFCF ratio
-81.57-100.54-6.59-1.76-4.78
P/B Ratio
8.0210.911.21.20.77
PTB ratio
8.0210.911.21.20.77
EV to sales
00000
Enterprise value over EBITDA
-77.93-88.48-1.78-1.69-2.98
EV to operating cash flow
-88.95-118.58-7.31-1.87-4.3
EV to free cash flow
-78.84-96.72-5.91-1.85-3.92
Earnings yield
-0.01-0.01-0.51-0.63-0.29
Free cash flow yield
-0.01-0.01-0.15-0.57-0.21
Debt to equity
0.090.110.110.190.21
Debt to assets
0.130.160.170.250.27
Net debt to EBITDA
2.73.50.2-0.080.65
Current ratio
16.9413.0811.226.876.08
Interest coverage
000-2.36K-472.28
Income quality
0.870.740.240.880.67
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.130.230.240.010.09
Capex to revenue
00000
Capex to depreciation
-17.03-27.55-6.82-1.22-1.6
Stock based compensation to revenue
00000
Graham number
15.9715.9130.2419.639.05
ROIC
-0.09-0.11-0.19-0.63-0.18
Return on tangible assets
-0.09-0.1-0.5-0.57-0.16
Graham Net
8.867.576.162.942.34
Working capital
542.06M490.83M411.33M220.62M185.36M
Tangible asset value
00000
Net current asset value
492.1M434.93M362.23M172.26M137.77M
Invested capital
0.090.110.220.20.23
Average receivables
00000
Average payables
12.4M8.97M11.41M9.13M9.5M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.1-0.12-0.61-0.76-0.22
Capex per share
-0.12-0.19-0.28-0.05-0.06

Frequently Asked Questions

What is Allakos Inc. stock symbol ?

Allakos Inc. is a US stock , located in Redwood city of California and trading under the symbol ALLK

Is Allakos Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $218. The lowest prediction is $218 and the highest is $218

What is ALLK stock prediction ?